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Results: Area under the curve was 0.78 with 95% confidence interval of 0.69-0.86. Two distinct thresholds that optimized
specificity and sensitivity were 0.36 (Youden method) and 0.25 (closest top left method); both are plotted on ROC curve in Figure
1. For the Youden method, the specificity was calculated as 81% and sensitivity as 69%. Negative predictive value was 85% and
positive predictive value was 62%. The 19 false positives showed FL in biopsy, including only one FL grade 3A, 14 FL grade 1-2,
and 4 FL that could not be graded.
Figure 1 - 915

Conclusions: Statistical analysis of FSC in transformed FL cases demonstrated that a threshold of 36% large cells optimizes
identification of the transformed subset while minimizing false positives per Youden J statistic. However, despite threshold
optimization, multiple false positives still occurred when relying only on the FSC parameters by FACS. Therefore, correlation with
intact tissue morphology is critical to prevent overcalling transformation.
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Background: MGRS is a relatively new concept for patients with renal paraprotein deposition (RPD) (except monoclonal cast
nephropathy) with no bone marrow confirmed diagnosis of malignancy or premalignancy (< 10% monoclonal plasma cells). This
concept has been used as a reason for a nephrology consult for a bone marrow biopsy (BMB), therefore it is important to evaluate
the outcome of MGRS tentatively diagnosed via renal biopsy and confirmed by BMB. This study’s purpose was to identify what
percentage of various subtypes of MGRS tentatively diagnosed via renal biopsy can be confirmed as MGRS by BMB and followup.
Design: In total, 124 renal biopsies with variants of RPD were identified at our center out of 3811 renal biopsies (3.3% of overall
cases) over past 10 years. Biopsy cases with known Myeloma, B Cell Lymphoma or Monoclonal Cast Nephropathy were separated
as a heavy burden group. The remaining biopsies with RPD were considered as tentative MGRS diagnoses. Their BMB and clinical
indices were followed up to determine the percent that resulted in a confirmed MGRS diagnosis.
Results: Among the 124 renal paraprotein deposition cases, 43 cases (34.7%) were categorized to the heavy burden group
(Figure). The remaining 81 cases with other variants of RPD were further divided into four categories based on the follow-up.
Myeloma or Lymphoma were found in 34 cases (27.4%). Twelve outside consultation cases (10%) did not show follow-up biopsies
as we were unable to obtain record access. BMB’s diagnosed as nonmalignant (6 cases, 4.8%) or premalignant (29 cases, 23.4%)
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were confirmed to be MGRS for a total of 35 cases (28.2%). Among the different categories of tentative MGRS, Monoclonal
Light/Heavy Chain Deposition Diseases (L/HCDD) had the highest positivity rate for myeloma on the subsequent BMB (Table).
Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposition (PGNMID) had a high rate of nonmalignant or premalignant diagnosis by BMB. Monoclonal Amyloidosis had some nonmalignant and pre-malignant diagnoses after BMB although
myeloma was associated with this renal entity (Table).
Different categories of RPD
L/H CDD
n = 19
Amyloidosis
n = 28
PGNMID
n=9
Proximal Tubulopathy n = 6
Cryoglobulin GN1
n=4
Immunotactoid GN1 n = 1
Fibrillary GN1
n=1
1

Malignant
15 (78.9%)
15 (53.6%)
1 (11.1%)
2 (33.3%)
1 (25.0%)
0
0

Nonmalignant
0
1 (3.5%)
4 (44.4%)
1 (16.7%)
0
0
0

Premalignant
4 (21.1%)
13 (42.9%)
4 (44.4%)
3 (50.0%)
3 (75.0%)
1 (100.0%)
1 (100.0%)

Confirmed MGRS
4 (21.1%)
14 (46.4%)
8 (88.8%)
4 (66.7%)
3 (75.0%)
1 (100.0%)
1 (100.0%)

GN: glomerulonephropathy
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Conclusions: The data indicate that BMB is crucial for confirming a diagnosis of MGRS. The study also provides pathologists and
clinicians with general expectations regarding the possible BMB outcome for the many variants of MGRS identified tentatively via
renal biopsy.
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Background: We and others have used flow cytometric (FCM) parameters to predict for MDS. We have found CD177+ neutrophils
in addition to the Ogata parameters (B cell progenitors percentage, blast percentage, low side scatter and CD45 blast expression)
as sensitive and specific for MDS compared to age-matched cytopenic controls. However, false positive FCM analyses occur in
roughly 10-15% of low-grade MDS cases mainly due to low B cell progenitor percentage in many cytopenic controls. We therefore
examined whether blast subset parameters in addition to the B cell progenitor percentage could be utilized to enhance the
specificity of FCM detection of MDS.
Design: 29 MDS cases (17 without excess blasts) and 27 cytopenic controls (negative by NGS, karyotype and morphology) were
evaluated. Blast subsets were determined similar to that used by Shameli et. al (PMID 33369070). A total of 100,000 events were
collected and CD34 cells were gated. CD34 subsets were enumerated based on 6 color analysis using a tube stained with CD71,
CD371, CD38, CD34, CD19 and CD45. Percentage of CD34+ cells that were CD371+CD38+ (GM-like), CD71+CD371- (erythroidlike), CD71-CD38dim/negative (stem-like), CD19+ (B cell progenitor) and other (none of the above) were determined. Cut-offs were
based on control samples and applied to the MDS cases. The percentage of cases showing 0, 1 or 2 or more abnormalities were
tallied.
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